Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · IEX Real-Time Price · USD
28.80
+0.31 (1.07%)
Jul 12, 2024, 1:04 PM EDT - Market open

Supernus Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 2009
Revenue
607.52667.24579.78520.4392.76
Upgrade
Revenue Growth (YoY)
-8.95%15.09%11.41%32.50%-3.95%
Upgrade
Cost of Revenue
83.7887.2275.0652.4616.66
Upgrade
Gross Profit
523.74580.02504.71467.94376.1
Upgrade
Selling, General & Admin
336.36377.22304.76200.68153.25
Upgrade
Research & Development
91.5974.5590.4775.9669.1
Upgrade
Other Operating Expenses
102.5782.6329.9917.65.18
Upgrade
Operating Expenses
530.53534.4425.22294.24227.52
Upgrade
Operating Income
-6.7945.6179.5173.7148.57
Upgrade
Interest Expense / Income
2.427.0723.4223.7522.71
Upgrade
Other Expense / Income
-11.97-22.2-17.1-18.7-21.62
Upgrade
Pretax Income
2.7760.7473.18168.65147.49
Upgrade
Income Tax
1.450.0319.7541.734.43
Upgrade
Net Income
1.3260.7153.42126.95113.06
Upgrade
Net Income Growth
-97.83%13.64%-57.92%12.29%1.86%
Upgrade
Shares Outstanding (Basic)
5554535352
Upgrade
Shares Outstanding (Diluted)
5662545454
Upgrade
Shares Change
-10.01%13.47%1.24%-0.24%-0.52%
Upgrade
EPS (Basic)
0.021.131.012.412.16
Upgrade
EPS (Diluted)
0.021.040.982.362.10
Upgrade
EPS Growth
-98.08%6.12%-58.47%12.38%2.44%
Upgrade
Free Cash Flow
110.53116.41125.08134.71141.74
Upgrade
Free Cash Flow Per Share
2.032.172.362.562.70
Upgrade
Gross Margin
86.21%86.93%87.05%89.92%95.76%
Upgrade
Operating Margin
-1.12%6.84%13.71%33.38%37.83%
Upgrade
Profit Margin
0.22%9.10%9.21%24.39%28.79%
Upgrade
Free Cash Flow Margin
18.19%17.45%21.57%25.89%36.09%
Upgrade
Effective Tax Rate
52.47%0.05%26.99%24.72%23.35%
Upgrade
EBITDA
90.04153.36129.19210.54176.85
Upgrade
EBITDA Margin
14.82%22.98%22.28%40.46%45.03%
Upgrade
Depreciation & Amortization
84.8685.5432.618.146.66
Upgrade
EBIT
5.1867.8196.6192.4170.19
Upgrade
EBIT Margin
0.85%10.16%16.66%36.97%43.33%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).